Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia.
Fabio GilFabian Juliao-BañosLuisa AmadorGamboa N CastañoJuan Manuel Reyes-SanchezPublished in: PharmacoEconomics - open (2022)
The analysis suggests that in Colombia, treatment with tofacitinib for patients with moderate-to-severe UC is a cost-effective option in both lines compared with other treatment options.